2026 Familial pulmonary arterial hypertension strategy: epidemiology, BMPR2 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Pulmonary capillary hemangiomatosis strategy: epidemiology, EIF2AK4 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Cardiac amyloidosis strategy: epidemiology, TTR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…

2026 Eisenmenger syndrome strategy: epidemiology, BMPR2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…

2026 Cardiac laminopathy strategy: epidemiology, LMNA biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…

2026 Phospholamban cardiomyopathy strategy: epidemiology, PLN biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Congenital lipodystrophy strategy: epidemiology, AGPAT2 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Primary osteoporosis in children strategy: epidemiology, Sclerostin biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Familial hypocalciuric hypercalcemia strategy: epidemiology, CaSR biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Familial tumoral calcinosis strategy: epidemiology, FGF23 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Pseudohypoparathyroidism strategy: epidemiology, PTH1R biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Progressive osseous heteroplasia strategy: epidemiology, GNAS biology, clinical competition, recent deals, unmet need and market attractiveness.